市場調查報告書
商品編碼
1422078
全球乳房 X 光攝影市場:按類型、技術、應用、最終用戶、地區、機會、預測,2017-2031 年Mammography Market Assessment, By Type, By Technology, By Application, By End-users, By Region, Opportunities and Forecast, 2017-2031F |
2023年全球乳房X光攝影市場規模為29.3億美元,預計在2024-2031年預測期內複合年增長率為8.68%,到2031年將達到57億美元。全球乳房X光檢查市場的成長受到多種因素的推動,例如乳癌盛行率上升、老年人口增加、技術進步、人工智慧的整合以及政府舉措、政策和計劃。私營和公共部門對成像解決方案的投資增加、多家頂級公司的存在以及合併、收購、聯盟和產品發布等策略正在推動全球乳房X線攝影市場的成長。由於世界各地乳癌盛行率不斷上升,全球乳房X光檢查市場正在強勁成長。2023年,美國將有297,790名女性被診斷出罹患侵襲性乳癌,55,720名女性將被診斷出罹患非侵襲性乳癌。在全球範圍內,乳癌是女性第五大死因。
為了更快地診斷,重要的是應用乳房X光檢查不僅用於篩檢,而且用於診斷目的。其他因素,例如在醫療機構中採用最新的乳房X光檢查技術以及將人工智慧整合到乳房X光檢查中以實現快速準確的檢測,都進一步加速了全球乳房X光檢查市場的成長。世界各國政府正在國家和國際層面製定政策和計劃,以提高對乳癌篩檢和適當管理的認識。這些努力吸引了公共和私人公司參與和投資研發,以提供高品質、先進的醫療保健。已開發國家對 3D 乳房 X 光檢查的需求正在增加。因為 3D 乳房 X 光檢查將診斷準確度提高了 25%,並將誤報數量減少了 15%。
全球乳癌盛行率的增加是推動全球乳房X光檢查市場的主要因素。據世界衛生組織稱,全球有超過 230 萬名女性被診斷出患有乳癌,超過 685,000 人死於乳癌。乳癌是女性最常見的癌症之一。乳癌家族史、過度吸煙和飲酒以及輻射暴露史是全球乳癌盛行率不斷上升的主要危險因子。乳房X光檢查等醫學影像技術在乳癌的早期診斷中發揮重要作用,因為它們是非侵入性程序,甚至可以在症狀出現之前檢測到癌細胞,因此幾十年來一直處於乳癌篩檢的最前沿。隨著發展中國家對乳癌篩檢技術的認識不斷提高,預計在預測期內對乳房X光檢查的需求也會增加。
該報告研究了全球乳房X光檢查市場,並提供了市場概述,包括按類型、技術、應用、最終用戶、地區和參與市場的公司概況劃分的趨勢。
Global Mammography Market size was valued at USD 2.93 billion in 2023 which is expected to reach USD 5.7 billion in 2031 with a CAGR of 8.68% for the forecast period between 2024 and 2031. Growth in the global mammography market is driven by various factors such as the rising prevalence of breast cancer, the increased number of geriatric populations, technological advancements, integration of artificial intelligence, government initiatives, policies, and programs. Increasing investments by private and public sectors in the imaging solutions, presence of several top players and strategies such as mergers, acquisitions, collaborations, and product launches are driving the global mammography market growth. The global mammography market is experiencing robust growth due to increasing prevalence of breast cancer across the world. 297,790 women in the United States were diagnosed with invasive breast cancer in 2023, while 55,720 women were diagnosed with non-invasive breast cancer. Globally, female breast cancer is the 5th leading cause of mortality.
For faster disease diagnosis, application of mammography for screening as well as diagnostic purpose is important. Other factors such as introduction of latest mammography technologies in healthcare facilities and integration of artificial intelligence in mammography for quick and accurate detection is further accelerating growth in global mammography market. Governments around the globe are setting up policies and programs at national and international level, to increase awareness regarding screening and proper management of breast cancer. These initiatives are attracting public and private companies to join and invest in research and development to provide quality and advanced medical treatment. Developed countries are experiencing increasing demand for 3D mammography, as it improves diagnostic accuracy by 25% and decreases the number of false positives by 15%.
The increasing prevalence of breast cancer, globally, is a major factor driving the global mammography market. As per WHO, more than 2.3 million women were diagnosed with breast cancer and more than 685,000 deaths accounted for breast cancer globally. Breast cancer is one of the most common forms of cancer for women. Family history of breast cancer, excessive tobacco and alcohol consumption, history of radiation exposure are the leading risk factors for the rising prevalence of breast cancer, around the world. Medical imaging technologies such as mammography play a crucial role in early diagnosis of breast cancer as it is a non-invasive procedure and can detect cancer cells, even before symptoms arises, this has made it the frontline breast cancer screening tool for several decades. With growing breast cancer awareness regarding screening techniques in developing countries, demand for mammography is also expected to increase in the forecasted period.
Today's world of digitalization and artificial intelligence has revolutionized advancement in mammography. Artificial intelligence has a significant role in mammography, offering several benefits such as improved accuracy and early diagnosis. In recent years, there has been a surge of innovative technologies to overcome traditional screening approaches' limitations. 3D mammography, also known as tomosynthesis or 3D breast imaging, offers several benefits over traditional 2D mammography such as improved cancer detection, reduced need for follow-up imaging, and gives imaging details of the three anatomical body planes-coronal, sagittal and transverse. Integration of AI in 3D mammography technique can further enhance diagnostic accuracy. Many medical device manufacturing companies are launching AI-integrated mammography devices to improve their product portfolio and for providing better health outcomes to the patients. For instance, on November 2023, GE HealthCare announced the launch MyBreastAI Suite, an all-in-one platform for artificial intelligence enabled mammography. This app has three AI applications from iCAD including ProFound AI for digital breast tomosynthesis, SecondLook for 2D mammography and PowerLook Density Assessment. This helps clinicians in early detection of breast cancer, by improving patient outcomes, and operational productivity.
Mammography improves treatment outcomes in patients by early detection and diagnosis of cancer cells, even before there are any signs and symptoms of cancer in the individual. As early detection and screening are the best approach for breast cancer, governments have initiated several policies and programs emphasizing the importance of screening breast cancer and are investing billions of dollars in research and development in healthcare facilities, including innovation in medical diagnosis techniques for mammography. For instance, WHO's Global Breast Cancer Initiative (GBCI), that was established in 2021 for a period of 20 years, was initiated with the aim to bring together stakeholders around the world and across different sectors with a common goal of reducing breast cancer by 2.5% each year. Global Breast Cancer Initiative is focussed on 3 key strategies to achieve these objectives: health promotion and early detection, timely diagnosis, and comprehensive breast cancer management.
Mammography is used for both screening and diagnostic purpose. However, with increasing government support in organizing and encouraging annual screening program, the application of mammography for screening purpose is witnessing a huge growth potential. Mammography application during screening is recommended for women who don't have any sign or symptoms of breast cancer. Mammography has the potential to detect even a small change or lesions in the breast, which makes it very popular among organizations for screening purposes. For instance, in May 2023, U.S. Preventive Services Task Force, stated that women aged between 40 and 74 years should have screening mammograms in every two years. This recommendation was made as more women in their 40s are diagnosed with breast cancer, thus screening at an earlier stage increase the chances of survival for the patient.
The global mammography market is expected to grow tremendously in the coming years due to multiple factors such as the increasing prevalence of breast cancer, increasing in the geriatric population, technological advancements, integration of AI for mammography screening, increasing popularity of 3D mammography and governmental initiatives, policies, and programs to enhance breast cancer screening. Increasing investments by public and private companies for research and development in the respective markets and collaborative ventures involving medical devices manufacturers and research institutions have spurred innovation leading to further growth of the global mammography market.
In the mammo gram market industry, several public and private companies are actively establishing strategic partnerships and distribution agreements to empower and strengthen resources and gain insights regarding new market and advanced technologies to expand their businesses globally. Mergers and acquisitions are being done with the aim of fostering innovation and improving product portfolios of medical device companies. For instance, in September 2023, Hologic Inc. and Bayer announced their international partnership to deliver contrast-enhanced mammography (CEM) solutions to improve breast cancer detection in multiple countries across the Canadian, European, and Asia Pacific regions. Along with breast cancer detection, this partnership also aims to assist radiologists and clinicians for providing quality medical treatment to the patients.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.